10-K Decoder · All companies

Iovance Biotherapeutics, Inc.

IOVA · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$264M$164M+60.6%
Operating income−$403M−$395M−2.0%
Net income−$391M−$372M−5.1%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026

$Q3 2026Year earlierChange
Revenue$122M$67.5M+80.0%
Operating income−$24.0M−$94.9M+74.7%
Net income−$22.3M−$91.3M+75.6%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Iovance's revenue in FY2025?
$264M in FY2025 (Fiscal year ended Dec 31, 2025), +60.6% vs $164M a year earlier, per its 10-K filed Feb 2026.
Was Iovance profitable in FY2025?
No: net income was −$391M and operating income −$403M in FY2025.
What was Iovance's revenue in Q3 2026?
$122M (+80.0% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.